Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAF(V600)-mutant resectable melanoma: the randomized phase 2 NeoTrio trial
新辅助治疗 pembrolizumab、dabrafenib 和 trametinib 治疗 BRAF(V600) 突变型可切除黑色素瘤：一项随机 II 期 NeoTrio 试验
期刊:Nature Medicine
影响因子:50
doi:10.1038/s41591-024-03077-5
Long, Georgina V; Carlino, Matteo S; Au-Yeung, George; Spillane, Andrew J; Shannon, Kerwin F; Gyorki, David E; Hsiao, Edward; Kapoor, Rony; Thompson, Jake R; Batula, Iris; Howle, Julie; Ch'ng, Sydney; Gonzalez, Maria; Saw, Robyn P M; Pennington, Thomas E; Lo, Serigne N; Scolyer, Richard A; Menzies, Alexander M
